Alkaline Phosphatase Replacement Therapy for Hypophosphatasia in Development and Practice

Area of Science:

• Genetics and Molecular Biology
• Metabolic Bone Diseases
• Enzyme Replacement Therapy

Background:

• Hypophosphatasia (HPP) is an inherited metabolic bone disorder caused by mutations in the ALPL gene, leading to deficient tissue-nonspecific alkaline phosphatase (TNSALP) activity.
• Reduced TNSALP activity results in the accumulation of pyrophosphate, inhibiting skeletal and dental mineralization, causing rickets, osteomalacia, fractures, and premature tooth loss.
• Historically, HPP management relied on supportive care, with limited options for addressing the underlying pathophysiology.

Purpose of the Study:

• To provide a comprehensive overview of Hypophosphatasia (HPP), including its genetic basis, clinical manifestations, and historical treatment approaches.
• To review the development, design, and validation of asfotase alfa (AA), a novel enzyme replacement therapy for HPP.
• To summarize the efficacy, safety, and future directions of AA therapy based on clinical trials and case reports.

Main Methods:

• Review of existing literature on HPP, ALPL gene, TNSALP function, and mineralization pathways.
• Analysis of preclinical data from HPP mouse models.
• Synthesis of findings from clinical trials and case reports evaluating asfotase alfa (AA) efficacy and safety.

Main Results:

• Asfotase alfa (AA) enzyme replacement therapy (ERT) has demonstrated significant improvements in survival for infants with severe HPP and enhanced quality of life in children and adults.
• AA ERT addresses the underlying enzyme deficiency, leading to improved bone mineralization and reduced skeletal complications.
• Clinical data indicate a positive therapeutic response to AA ERT, alongside an assessment of adverse effects, limitations, and ongoing research.

Conclusions:

• Asfotase alfa (AA) ERT represents a paradigm shift in HPP management, offering a targeted therapy for this debilitating genetic disorder.
• The efficacy and safety profile of AA ERT support its role in improving clinical outcomes and quality of life for HPP patients.
• Further research and long-term follow-up are essential to fully understand the potential and limitations of AA ERT and to explore future therapeutic strategies.